Crystal Research Associates Issues Executive Informational Overview (EIO) on Catasys
NEW YORK, Sept. 21, 2015 /PRNewswire/ -- Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview® (EIO) on Catasys, Inc. (CATS-OTCQB). The full 56-page report is available on Crystal Research Associates' website at www.crystalra.com.
Catasys, Inc. (or "the Company") provides big data–based analytics and predictive modeling–driven health management services for health plans. These services aim to improve member health while simultaneously lowering insurer costs for underserved populations. Catasys' OnTrak™ integrated solutions serve individuals who have behavioral health disorders that exacerbate coexisting medical conditions, resulting in higher hospital admissions and emergency room (ER) visits.
The Company has developed analytics for identifying which individuals on an insurance plan are "high utilizers" with impactable costs due to having behavioral conditions such as substance dependency or anxiety disorder. Catasys targets these patients with its proprietary direct outreach capability to enroll them in the OnTrak™ patient-centric treatment program. OnTrak™ integrates evidence-based medical and psychosocial interventions in a 52-week outpatient program that has shown a 50%+ reduction in total costs for members enrolled in its programs—stemming from decreases in hospital stays, ambulance usage, and ER visits. The Company has entered into contracts with several insurance providers for OnTrak™, which is now available in 10 states, including through Aetna/Coventry, Humana, Centene, Fallon Health, Health Alliance Medical Plans, and Reliant Medical Group. Collectively, this entails approximately 2.3 million Commercially Equivalent Lives (CELs). Catasys' pipeline includes 10 million additional CELs, with 4 million in advanced discussions. CELs are a metric of growth potential, as increasing CELs may represent future contracts and increasing future enrollment.
Be the first to hear about Crystal Research's new report releases and upcoming media coverage. Follow us at http://www.crystalra.com/blog for more coverage.
About Crystal Research Associates, LLC
For the past decade, Crystal Research Associates, LLC (www.crystalra.com) has successfully articulated the exceptional stories of small- and mid-cap companies to the Wall Street investor community. Our methods are well-established and diverse, from compiling and disseminating objective, factual information for both institutional and retail investor audiences to capitalizing on our expansive line of targeted distribution channels, which include industry-leading financial data and information providers. Our distribution efforts are accompanied by the use of prominent social media channels and by strategic and targeted appearances on national news programs and print media.
Crystal Research Associates is led by Wall Street veterans, Jeffrey Kraws and Karen Goldfarb. Together, Kraws and Goldfarb have built a unique business model, capitalizing on decades of experience as an award-winning sell-side analyst team to produce institutional-quality industry and market research in a manner that is easily understood by investors and consumers. Our firm's approach has been proven successful over the years as our products are published and available on Bloomberg, Thomson Reuters/First Call, Capital IQ, FactSet, Yahoo! Finance, and scores of other popular forums.
About Catasys, Inc.
Catasys, Inc. provides big data based analytics and predictive modeling driven behavioral healthcare services to health plans and their members through its OnTrak program. Catasys' OnTrak program--contracted with a growing number of health insurers--is designed to improve member health and, at the same time, lower costs to the insurer for underserved populations where behavioral health conditions cause or exacerbate co-existing medical conditions. The program utilizes proprietary analytics and proprietary enrollment, engagement and behavioral modification capabilities to assist members who otherwise do not seek care through a patient-centric treatment that integrates evidence-based medical and psychosocial interventions along with care coaching in a 52-week outpatient program. OnTrak is currently improving member health and, at the same time, is demonstrating reduced inpatient and emergency room utilization, driving a more than 50% reduction in total health insurers' costs for enrolled members. Catasys currently operates OnTrak in Florida, Illinois, Kansas, Kentucky, Louisiana, Massachusetts, New Jersey, Oklahoma, West Virginia and Wisconsin. For further information, please visit catasys.com.
Forward-Looking Safe Harbor Statement
Statements in this news release and the EIO regarding future financial and operating results, current and future opportunities for the Company, the ability of the Company to execute its business plan and achieve profitably, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including limited operating history, need for future capital, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic news and SEC reports the Company files with the Securities and Exchange Commission. These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Crystal Research Associates assumes no obligation to update any of the forward-looking statements in this release, except as required by law.
Crystal Research Associates' compensation for issuing the EIO is a cash amount of $45,000 and warrants to purchase 300,000 shares of common stock of the Company.
SOURCE Catasys, Inc.
Share this article